Strategic Communication and Public Relations

What determines the identity of cells

No. 19c2 | 31/03/2020 | by Koh

Scientists from the Hector Institute for Translational Brain Research and Stanford University showed in mice how so-called pioneer factors determine the identity of nerve and muscle cells. During embryonic development, these factors ensure that the various body cells can form. In laboratory experiments, pioneer factors can even be used to transform cell types, for example skin cells into nerve cells. This allows scientists to obtain specific cell types for their research.

The Hector Institute for Translational Brain Research (HITBR) is funded by the Central Institute of Mental Health, the German Cancer Research Center and the Hector Foundation II.

“Pioneer factors” reprogram connective tissue cells in the culture dish to become nerve cells (red) and muscle cells (green).
© Mall/DKFZ

Transcription factors can switch on individual genes and are thus enabling cells to develop their specialized identity and function in the body. Some of these factors can even change or re-programme the identity of the cells, for example when they are artificially introduced into cells by viruses. Using this technology, scientists can already reprogram skin or blood cells into nerve or stem cells and use them for research into diseases.

Moritz Mall at the German Cancer Research Center (DKFZ, HITBR) and Qian Yi Lee at Stanford University compared two transcription factors that are structurally similar but induce completely different cell types. The factor Ascl1 can program skin cells into nerve cells, while Myod1 can convert skin cells into muscle cells.

Since transcription factors normally exert their effect by binding certain gene switches, the researchers first investigated the DNA binding sites of both factors. Although Ascl1 and Myod1 induce very different cell types, both surprisingly bind to largely overlapping recognition sequences in the mouse genome. This is true both during reprogramming and during normal cell differentiation. "For us, this was an indication that other mechanisms must be involved to ensure that only the desired genes are regulated," explains Mall. In fact, further analyses showed that despite the overlap, Ascl1 and Myod1 each attached to specific regions of the genome with stronger binding power.

"We were able to decipher on a molecular level how the pioneer factors Ascl1 and Myod1 function and that they are also prone to errors due to their incredible binding power," explains Moritz Mall. "That's why co-factors like the Guardians are important: they keep the pioneer factors in check. Mutations in guardian factors are associated with diseases such as cancer, which underlines their important role."

The scientists want to use their new findings to produce specific cell types for research with even greater precision. Their future goal is to be able to investigate brain diseases in the culture dish in the future.

The work at the DKFZ and HITBR was funded by the Hector Foundation II and the European Research Council ERC, among others.

Qian Yi Lee, Moritz Mall, Soham Chanda, Bo Zhou, Kylesh S. Sharma, Katie Schaukowitch, Juan M. Adrian-Segarra, Sarah D. Grieder, Michael S. Kareta, Orly L. Wapinski, Cheen Euong Ang, Rui Li, Thomas C. Südhof, Howard Y. Chang, Marius Wernig: Pro-neuronal activity of Myod1 due to promiscuous binding to neuronal genes.
Nature Cell Biology 2020, DOI: 10.1038/s41556-020-0490-3

A picture is available for Download: 

Photo caption: "Pioneer factors" reprogram connective tissue cells in the culture dish to become nerve cells (red) and muscle cells (green).

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Mall/DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: Any commercial use is prohibited.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS